Updated: Jan 11
"IntraBio Ltd. is pleased to confirm that it has completed recruitment for its Pivotal Trial, Effects of N-Acetyl-L-Leucine on Niemann-Pick disease type C (NPC): A Phase III, randomized, placebo-controlled, double-blind, crossover study (IB1001-301 - NCT05163288)."
Read the full article here:
70+ NPC patients were screened across 13 trial sites in Australia, Europe, United Kingdom and United States.
The trial was able to be over-enrolled by approximately 130% and the data-read is expected out in June 2023.
Multiple Australian patients were recruited and will have their first screening visit this month!
To join our fight, as well as fund vital research for a cure, support the Australian NPC Disease Foundation in its goals of "Research. Cure. Persevere."
Ways to support NP-C in Australia: